---
document_datetime: 2025-11-23 08:03:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nivolumab-bms.html
document_name: nivolumab-bms.html
version: success
processing_time: 0.1091245
conversion_datetime: 2025-12-27 13:49:50.924134
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nivolumab BMS

[RSS](/en/individual-human-medicine.xml/66551)

##### Withdrawn

This medicine's authorisation has been withdrawn

nivolumab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nivolumab BMS](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 30 November 2015, the European Commission withdrew the marketing authorisation for Nivolumab BMS (nivolumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Bristol-Myers Squibb Pharma EEIG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Nivolumab BMS was granted marketing authorisation in the EU on 20 July 2015 for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. The marketing authorisation was initially valid for a 5-year period.

Nivolumab BMS is identical to Opdivo, which is also authorised in the EU to treat squamous NSCLC as well as melanoma. The marketing authorisation holder has committed to ensure that patients who need treatment with Nivolumab BMS continue to receive it until complete exhaustion of stock. Patients with squamous NSCLC currently being treated with Nivolumab BMS will then be automatically switched to Opdivo.

The European Public Assessment Report (EPAR) for Nivolumab BMS is updated accordingly to indicate that the marketing authorisation is no longer valid.

Nivolumab BMS : EPAR - Summary for the public

English (EN) (545.33 KB - PDF)

**First published:** 27/07/2015

**Last updated:** 14/01/2016

[View](/en/documents/overview/nivolumab-bms-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-190)

български (BG) (628.52 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/bg/documents/overview/nivolumab-bms-epar-summary-public_bg.pdf)

español (ES) (545.63 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/es/documents/overview/nivolumab-bms-epar-summary-public_es.pdf)

čeština (CS) (613.18 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/cs/documents/overview/nivolumab-bms-epar-summary-public_cs.pdf)

dansk (DA) (543.18 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/da/documents/overview/nivolumab-bms-epar-summary-public_da.pdf)

Deutsch (DE) (549.23 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/de/documents/overview/nivolumab-bms-epar-summary-public_de.pdf)

eesti keel (ET) (542.1 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/et/documents/overview/nivolumab-bms-epar-summary-public_et.pdf)

ελληνικά (EL) (636.28 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/el/documents/overview/nivolumab-bms-epar-summary-public_el.pdf)

français (FR) (546.72 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fr/documents/overview/nivolumab-bms-epar-summary-public_fr.pdf)

hrvatski (HR) (571.17 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hr/documents/overview/nivolumab-bms-epar-summary-public_hr.pdf)

italiano (IT) (542.76 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/it/documents/overview/nivolumab-bms-epar-summary-public_it.pdf)

latviešu valoda (LV) (609.52 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lv/documents/overview/nivolumab-bms-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (574.01 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lt/documents/overview/nivolumab-bms-epar-summary-public_lt.pdf)

magyar (HU) (606.5 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hu/documents/overview/nivolumab-bms-epar-summary-public_hu.pdf)

Malti (MT) (614.46 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/mt/documents/overview/nivolumab-bms-epar-summary-public_mt.pdf)

Nederlands (NL) (544.3 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/nl/documents/overview/nivolumab-bms-epar-summary-public_nl.pdf)

polski (PL) (611.69 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pl/documents/overview/nivolumab-bms-epar-summary-public_pl.pdf)

português (PT) (545.66 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pt/documents/overview/nivolumab-bms-epar-summary-public_pt.pdf)

română (RO) (573.04 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/ro/documents/overview/nivolumab-bms-epar-summary-public_ro.pdf)

slovenčina (SK) (612.68 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sk/documents/overview/nivolumab-bms-epar-summary-public_sk.pdf)

slovenščina (SL) (603.45 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sl/documents/overview/nivolumab-bms-epar-summary-public_sl.pdf)

Suomi (FI) (542.08 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fi/documents/overview/nivolumab-bms-epar-summary-public_fi.pdf)

svenska (SV) (544.15 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sv/documents/overview/nivolumab-bms-epar-summary-public_sv.pdf)

Nivolumab BMS : EPAR - Risk-management-plan summary

English (EN) (575.85 KB - PDF)

**First published:** 27/07/2015

**Last updated:** 14/01/2016

[View](/en/documents/rmp-summary/nivolumab-bms-epar-risk-management-plan-summary_en.pdf)

## Product information

Nivolumab BMS : EPAR - Product Information

English (EN) (1.18 MB - PDF)

**First published:** 27/07/2015

**Last updated:** 14/01/2016

[View](/en/documents/product-information/nivolumab-bms-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-209)

български (BG) (2.03 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/bg/documents/product-information/nivolumab-bms-epar-product-information_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/es/documents/product-information/nivolumab-bms-epar-product-information_es.pdf)

čeština (CS) (1.65 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/cs/documents/product-information/nivolumab-bms-epar-product-information_cs.pdf)

dansk (DA) (1.17 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/da/documents/product-information/nivolumab-bms-epar-product-information_da.pdf)

Deutsch (DE) (1.19 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/de/documents/product-information/nivolumab-bms-epar-product-information_de.pdf)

eesti keel (ET) (1.19 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/et/documents/product-information/nivolumab-bms-epar-product-information_et.pdf)

ελληνικά (EL) (2.15 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/el/documents/product-information/nivolumab-bms-epar-product-information_el.pdf)

français (FR) (1.21 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fr/documents/product-information/nivolumab-bms-epar-product-information_fr.pdf)

hrvatski (HR) (1.28 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hr/documents/product-information/nivolumab-bms-epar-product-information_hr.pdf)

íslenska (IS) (1.18 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/is/documents/product-information/nivolumab-bms-epar-product-information_is.pdf)

italiano (IT) (1.24 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/it/documents/product-information/nivolumab-bms-epar-product-information_it.pdf)

latviešu valoda (LV) (1.75 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lv/documents/product-information/nivolumab-bms-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.25 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lt/documents/product-information/nivolumab-bms-epar-product-information_lt.pdf)

magyar (HU) (1.7 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hu/documents/product-information/nivolumab-bms-epar-product-information_hu.pdf)

Malti (MT) (1.79 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/mt/documents/product-information/nivolumab-bms-epar-product-information_mt.pdf)

Nederlands (NL) (1.18 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/nl/documents/product-information/nivolumab-bms-epar-product-information_nl.pdf)

norsk (NO) (1.19 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/no/documents/product-information/nivolumab-bms-epar-product-information_no.pdf)

polski (PL) (1.7 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pl/documents/product-information/nivolumab-bms-epar-product-information_pl.pdf)

português (PT) (1.19 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pt/documents/product-information/nivolumab-bms-epar-product-information_pt.pdf)

română (RO) (1.31 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/ro/documents/product-information/nivolumab-bms-epar-product-information_ro.pdf)

slovenčina (SK) (1.61 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sk/documents/product-information/nivolumab-bms-epar-product-information_sk.pdf)

slovenščina (SL) (1.71 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sl/documents/product-information/nivolumab-bms-epar-product-information_sl.pdf)

Suomi (FI) (1.19 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fi/documents/product-information/nivolumab-bms-epar-product-information_fi.pdf)

svenska (SV) (1.12 MB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sv/documents/product-information/nivolumab-bms-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** - 30/11/2015

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nivolumab BMS : EPAR - All Authorised presentations

English (EN) (509.85 KB - PDF)

**First published:** 27/07/2015

**Last updated:** 14/01/2016

[View](/en/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-453)

български (BG) (537.8 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/bg/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_bg.pdf)

español (ES) (503.86 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/es/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_es.pdf)

čeština (CS) (528.93 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/cs/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (510.65 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/da/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (493.2 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/de/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (505.43 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/et/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (542.93 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/el/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_el.pdf)

français (FR) (508.59 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fr/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (523.42 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hr/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (501.36 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/is/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_is.pdf)

italiano (IT) (509.56 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/it/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (520.51 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lv/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (504.28 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/lt/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (531.87 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/hu/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (538.91 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/mt/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (501.83 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/nl/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (491.63 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/no/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_no.pdf)

polski (PL) (521.37 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pl/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_pl.pdf)

português (PT) (502.15 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/pt/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_pt.pdf)

română (RO) (508.84 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/ro/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (534.83 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sk/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (528.23 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sl/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (505.23 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/fi/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (502.42 KB - PDF)

**First published:**

27/07/2015

**Last updated:**

14/01/2016

[View](/sv/documents/all-authorised-presentations/nivolumab-bms-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nivolumab BMS Active substance nivolumab International non-proprietary name (INN) or common name nivolumab Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01XC17

### Pharmacotherapeutic group

- Antineoplastic and immunomodulating agents
- Monoclonal antibodies

### Therapeutic indication

Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

## Authorisation details

EMA product number EMEA/H/C/003840 Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 21/05/2015 Marketing authorisation issued 20/07/2015 Withdrawal of marketing authorisation 30/11/2015

## Assessment history

## Initial marketing authorisation documents

Nivolumab BMS : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/392114/2015

English (EN) (6.44 MB - PDF)

**First published:** 27/07/2015

**Last updated:** 14/01/2016

[View](/en/documents/assessment-report/nivolumab-bms-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nivolumab BMS

Adopted

Reference Number: EMA/CHMP/310230/2015

English (EN) (526.13 KB - PDF)

**First published:** 22/05/2015

**Last updated:** 14/01/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nivolumab-bms_en.pdf)

#### News on Nivolumab BMS

[New treatment option for patients with advanced lung cancer](/en/news/new-treatment-option-patients-advanced-lung-cancer) 22/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2015) 22/05/2015

**This page was last updated on** 14/01/2016

## Share this page

[Back to top](#main-content)